BrainX

Person-specific therapeutics for patients with rare brain disorders, created using patient’s genome, clinical data and daily habits powered by an AI engine. Tested and re-design through a single person clinical trial.

An estimated 200,000 people in the United States experience a Rare (orphan) Brain Disorder. These conditions don't have a cure and the treatments available sometimes are ineffective, expensive and have some serious side effects. That’s why we need precision medicine which is an emerging approach for disease treatment that takes into account individual variability in genes, environment, and lifestyle; this method promises to reduce medical errors, side effects and costs of medical care while improving efficiency or treatments and quality of life.

I'm a Medical Doctor with excellent professional and academic background as well as an outstanding entrepreneurial experience. I attended the 4th MIT Global Entrepreneurship Bootcamp last year, and now I'm an Entrepreneurship Mentor for the MIT Bootcamps, recently I mentored the first MIT IoT Bootcamp and the first Innovation in Education Bootcamp. I'm also a Community TA for all the MIT Bootcamp MOOCs on edX, so I have an extensive understanding of the 24 Steps of Disciplined Entrepreneurship framework.

Children that are currently experiencing a Rare Brain Disorder including Creutzfeldt-Jakob Disease and other uncurable diseases that affects about 200,000 children only in the US. In other developing countries like Mexico, children with these conditions don't have many options in regards of therapeutics. That's why this approach will be beneficial for them in developing economies.

Ensure agreement in the short term. - Agreement with ministry of health of developing countries like Mexico.

Perform an N=1 clinical trial and receive approvement for the regulatory agency in the developing country. - At least produce 1 therapeutic in the first year through an N=1 clinical trial.

Track how the AI engine produce therapeutics and analyze data. - Reproduce the model and scale the process to train the AI engine and help more children.

Using our data base and our AI software we will design therapeutics specified in DNA code. The resulting model is compiled using a DNA synthesizer, producing DNA which we introduced into a living cell, tested and redesigned until regulatory approval. We will be able to offer our therapeutics for almost no cost, being pioneers in a whole new paradigm in R&D.

We use a precision-medicine approach that considers individual variability in genes, environment and lifestyle. A unique approach that consider each person as a whole, unique human being.

We'll make strategic agreements with the Ministry of Health of each developing country that we're trying to help. By doing these partnerships, we'll guarantee coverage of our services and critical alliances with local industry. So far we have an agreement with the National Genomics Institute and the National Institute for Neurology and Neurosurgery in Mexico that allows us to increase our capacity to deploy R&D.

So far this project has been self-funded. However, we're looking for strategic partnerships to scale and finance upcoming projects. We have already partnerships with the National Genomics Institute, the National Institute of Neurology and Neurosurgery of Mexico as well as the biggest public University in Mexico, University of Guadalajara. These partnerships allow us to deploy our R&D more efficiently. We're planning to develop our first trial in the upcoming years with the support of the local regulatory agency (COFEPRIS).

Each country legal framework is a challenge. But we're confident that our team and technology will allow us to overcome this. Furthermore, our approach of providing personalized therapeutic to orphan diseases has been widely used before in other countries like the US. So we're confident that with the right partnerships we'll be able to create a sustainable and profitable startup in the short term.

Everything that I can, I'll return to the community as much as I can.

National Genomics Institute in Mexico
National Institute of Neurology and Neurosurgery
University of Guadalajara

Other pharma companies that target orphan diseases.